Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 212 of 6351
-
Experimental tumor injection aims to supercharge immunotherapy in rare skin cancer
Disease control Recruiting nowThis Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 1…
Phase 2/3 • Sponsor: TuHURA Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a laser scan catch mouth cancer before it spreads?
Diagnosis CompletedThe "Real-time molecular diagnosis of oral precancer" or the LIP study is testing a new device for the detection of cancer in the mouth. Oral cancers are serious and devastating illnesses, especially if detected at a late stage. Currently, the detection of oral cancer relies on …
Sponsor: King's College London • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
Could a common diabetes drug slash heart risks in hypertension?
Disease control Recruiting nowHypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) a…
Phase 3 • Sponsor: Prof. Dr. med. Ingo Eitel • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Hope for Platinum-Resistant ovarian cancer: new pill takes on chemo
Disease control Recruiting nowThe purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Triple threat: new combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart head and neck cancer
Disease control Recruiting nowThe purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamo…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
Disease control Not yet recruitingThis trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA positivity or stable disease after three IC cycles. The…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New vaccine aims to outsmart pneumonia bacteria
Prevention OngoingThe primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses …
Phase 3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Immune boosters take on brain cancer: new trial launches
Disease control Recruiting nowGIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in …
Phase 2 • Sponsor: Duke University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug TAK-928 takes on tough lung cancer in major trial
Disease control Recruiting nowLung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This …
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Weight-Loss drug cure sleep apnea without a machine?
Disease control Recruiting nowThis Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New immunotherapy cocktail aims to stall pancreatic cancer after chemo
Disease control Recruiting nowPhase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to spare bladders in cancer patients
Disease control Recruiting nowThis phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadj…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new eye drop tame uveitis inflammation without steroids?
Disease control OngoingThis is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Phase 3 • Sponsor: VivaVision Biotech, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for kids with rare epilepsy: first human trial launches
Disease control Recruiting nowStudy CL1-230815-001 (KANDLE) is a Phase Ib/II, First In Human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effect of S230815 in pediatric participants with KCNT1-related Developmental E…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Faith-Based therapy aims to heal trauma in young women
Symptom relief OngoingThis randomized controlled trial evaluates Mpata Yathu ("Our Space"), a trauma-informed, church-based counseling intervention for adolescent girls and young women in Lusaka, Zambia who have experienced gender-based violence and are living with or at risk for HIV. The intervention…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New pill could help kids with dwarfism grow better
Disease control Recruiting nowThis is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Ph…
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New eye implant could slow vision loss in diabetes
Disease control Recruiting nowThe purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into …
Phase 3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Spinal stimulation may reawaken paralyzed arms — a trial puts it to the test
Disease control Recruiting nowThis study aimed to determine whether cervical spinal cord epidural electrical stimulation (EES) can activate upper-limb muscles in individuals with spinal cord injury.
Sponsor: Buddhist Tzu Chi General Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a 90-Minute session curb suicidal thoughts? new trial aims to find out
Symptom relief Recruiting nowThe goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will b…
Sponsor: Unity Health Toronto • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC